Klee Justin B. 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Feb 6, 2025
Insider Transaction Report
Form 4
Klee Justin B.
DirectorCo-Chief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-05$1.57/sh+36,310$57,007→ 3,201,243 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-05−36,310→ 0 totalExercise: $1.57Exp: 2025-02-26→ Common Stock (36,310 underlying)
Footnotes (1)
- [F1]This option is fully vested and exercisable.